Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes
ConclusionsThis study represents the largest case series of primary R-RPLND for the treatment of low-stage non-seminomatous germ cell tumors (NSGCT). With 47 months of follow-up and a low rate of adjuvant chemotherapy, intermediate oncologic efficacy appears to be comparable to the gold standard open approach.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Germ Cell Tumors | Statistics | Study | Testicular Cancer | Urology & Nephrology